Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein
therapeutics company focused on orphan indications, announces that it
will release financial results for the three and nine months ended
September 30, 2015 prior to the market open on Tuesday, November 10,
2015.
Kamada management will host an investment community conference call on
Tuesday, November 10, 2015 at 8:30 a.m. Eastern time to discuss these
results and answer questions. Shareholders and other interested parties
may participate in the conference call by dialing 888-803-5993 (from
within the U.S.), 706-634-5454 (from outside the U.S.) or 1-809-315-362
(toll-free from Israel) and entering the conference identification
number: 75038084. The call will also be webcast live on the internet on
the Company’s website at www.kamada.com.
A replay of the call will be accessible two hours after its completion
through November 16, 2015 by dialing 855-859-2056 (from within the U.S.)
or 404-537-3406 (from outside the U.S.) and entering the conference
identification number: 75038084. The call will also be archived for 90
days on the Company’s website at www.kamada.com.
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for
immunomodulation orphan indications, and has a commercial product
portfolio and a robust late-stage product pipeline. The Company uses its
proprietary platform technology and know-how for the extraction and
purification of proteins from human plasma to produce Alpha-1
Antitrypsin (AAT) in a highly-purified, liquid form, as well as other
plasma-derived proteins. AAT is a protein derived from human plasma with
known and newly-discovered therapeutic roles given its immunomodulatory,
anti-inflammatory, tissue-protective and antimicrobial properties. The
Company’s flagship product is Glassia®, the first and only liquid,
ready-to-use, intravenous plasma-derived AAT product approved by the
U.S. Food and Drug Administration. Kamada markets Glassia in the U.S.
through a strategic partnership with Baxalta. In addition to Glassia,
Kamada has a product line of nine other injectable pharmaceutical
products that are marketed through distributors in more than 15
countries, including Israel, Russia, Brazil, India and other countries
in Latin America, Eastern Europe and Asia. Kamada has five late-stage
plasma-derived protein products in development, including an inhaled
formulation of AAT for the treatment of AAT deficiency that completed
pivotal Phase 2/3 clinical trials in Europe and entered Phase 2 clinical
trials in the U.S. Kamada also leverages its expertise and presence in
the plasma-derived protein therapeutics market by distributing 10
complementary products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E
of the U.S. Securities Exchange Act of 1934, as amended, and the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements are statements that are not
historical facts, such as statements regarding assumptions and results
related to financial results forecast, commercial results, timing and
results of clinical trials and EMA and U.S. FDA authorizations.
Forward-looking statements are based on Kamada’s current knowledge and
its present beliefs and expectations regarding possible future events
and are subject to risks, uncertainties and assumptions. Actual results
and the timing of events could differ materially from those anticipated
in these forward-looking statements as a result of several factors
including, but not limited to, unexpected results of clinical trials,
delays or denial in the U.S. FDA or the EMA approval process, additional
competition in the AATD market or further regulatory delays. The
forward-looking statements made herein speak only as of the date of this
announcement and Kamada undertakes no obligation to update publicly such
forward-looking statements to reflect subsequent events or
circumstances, except as otherwise required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151105005314/en/
Copyright Business Wire 2015